Oculis (OCS) AGM 2026 summary

Opening remarks and agenda

• Meeting convened in compliance with statutory notice and agenda published in the Swiss Official Gazette of Commerce on April 21, 2026.

• All formalities fulfilled, meeting declared open with no objections raised.

• Secretary, vote counter, auditors, independent proxy, and notary introduced; voting procedures explained.

Financial performance review

• Cash and short-term investments reached CHF 213.0 million ($268.7 million), up from CHF 98.7 million ($109.0 million) at end of 2024, mainly due to $210.0 million in equity financings.

• FY2025 net loss was CHF 99.0 million ($119.1 million), up from CHF 85.8 million ($97.4 million) in FY2024, reflecting increased R&D and personnel costs.

• Research and development expenses accounted for 69% of total operating expenses, rising to CHF 57.1 million ($68.7 million), driven by the OCS-01 DIAMOND program.

Strategic initiatives and plans

• Significant progress across three late-stage assets: OCS-01, Licaminlimab, and Privosegtor, with multiple Phase 3 and registrational trials underway.

• OCS-01 in two phase III programs (DIAMOND-1 and DIAMOND-2) with over 800 patients; topline results expected June 2026, NDA submission for DME planned Q4 2026, approval anticipated Q4 2027.

• Licaminlimab advanced as a precision medicine for dry eye disease; PREDICT-1 trial started end of 2025, topline readout anticipated Q4 2026.

• Privosegtor received Breakthrough Therapy and PRIME designations; three PIONEER registrational trials in optic neuropathies running concurrently to accelerate timelines.

• Expanded leadership team and strong balance sheet with no debt and cash runway into 2H 2029, excluding a CHF100m loan facility.